semaglutide fda approved indications A New Indication for (Wegovy) https://bit.ly/3UmgXaj The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy) has been by the to reduce the risk… Wegovy FDA Approval: CV Risk

Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: A systematic review and meta-analysis

For side effects that continue, heres what you should know

Both semaglutide and tirzepatide activate the same appetite-suppressing pathways in your brain, but they do so through different mechanismsand this distinction matters for gastrointestinal comfort

The limited duration and small sample size may have contributed to the lack of behavioral effects, and ongoing trials are exploring repeated dosing strategies (e.g., NCT06252623, NCT06691243)

2021;11:e12432

Consulting a healthcare provider is essential, as personalized factors like comorbidities and goals will guide the decision, as emphasized in Understanding the Differences Between Semaglutide and Tirzepatide